Zydus Lifesciences Limited, a leading global innovation-driven life-sciences company, is poised to launch its semaglutide injection in India on the first day of patent expiry. The launch will bring this groundbreaking treatment for Type 2 diabetes mellitus and obesity to patients under the brand names SEMAGLYN™, MASHEMA™, and ALTERME™.
This comes after receiving approval from the Drug Controller General of India (DCGI) to manufacture and market the injection.
One of the standout features of Zydus' semaglutide offering is its unique, indigenously developed drug delivery system. Unlike traditional treatments that require patients to purchase multiple single-dose pens to adjust dosages, Zydus’ semaglutide will be delivered through an innovative, reusable pen. This adjustable pen allows patients to seamlessly select and administer varying doses from a single unit, ensuring greater convenience, reducing treatment costs, and boosting patient adherence.
For your daily dose of medical news and updates, visit: HEALTH
Dr Sharvil Patel, Managing Director of Zydus Lifesciences Limited, expressed, “Zydus' innovative offering of Semaglutide is a major leap in patient-centric care. We are not just introducing a vital therapy to the market; we aim to elevate the standard of care. With a first-of-its-kind drug delivery mechanism in India, we’re simplifying treatment, enhancing adherence, and driving better long-term clinical outcomes for patients.”
Zydus holds exclusive rights to the novel, adjustable pen, which can deliver all approved strengths for the treatment of Type 2 diabetes mellitus and obesity. The reusable nature of the pen makes it a cost-effective option for patients, aligning with the company's mission to make critical therapies more accessible.
Diabetes and obesity represent pressing public health issues in India, with the International Diabetes Federation reporting that 8.9 crore adults in the country are living with diabetes, approximately 10. per cent of the adult population.
